Latest News
Crescent Biopharma, Inc.
- Crescent Biopharma, Inc. Estimates – BOATS:CBIO
- H.C. Wainwright reiterates Crescent Biopharma stock rating at buy By Investing.com
- Stifel reiterates Crescent Biopharma stock rating on pipeline progress
- Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
- Crescent Biopharma advances cancer drug trials across portfolio
- Crescent Biopharma advances cancer trials with CR-001 combos, targets Phase 3 start in early 2028
- Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional
- Crescent Biopharma (CBIO) Slips 3.02% to $14.46 as Shares Drift Toward Key Support - Jurik MA
- Crescent Biopharma Announces Grants of Inducement Awards
- FDA clears Crescent Biopharma's PD-L1-targeted ADC CR-002 for solid tumours
- Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
- The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady (NASDAQ:CBIO)
Headlines from the last 30 days, linking to the original publishers. See all market news →